Aprea Therapeutics, Inc. financial data

Symbol
APRE on Nasdaq
Location
Doylestown, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 16 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 553% % -36%
Return On Equity -96% % -78%
Return On Assets -74% % -64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,452,452 shares 109%
Common Stock, Shares, Outstanding 8,192,538 shares 49%
Entity Public Float $8,600,000 USD -14%
Common Stock, Value, Issued $8,192 USD 49%
Weighted Average Number of Shares Outstanding, Basic 6,538,722 shares 19%
Weighted Average Number of Shares Outstanding, Diluted 6,538,722 shares 19%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $6,476,560 USD 0.28%
Operating Income (Loss) $13,233,836 USD 7.6%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $12,599,569 USD 2.8%
Earnings Per Share, Basic -1.93 USD/shares 18%
Earnings Per Share, Diluted -1.93 USD/shares 18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $14,599,347 USD -36%
Assets, Current $15,561,246 USD -34%
Property, Plant and Equipment, Net $59,807 USD -27%
Other Assets, Noncurrent $271,162 USD -3.7%
Assets $15,933,401 USD -34%
Accounts Payable, Current $713,668 USD -47%
Employee-related Liabilities, Current $770,562 USD 66%
Liabilities, Current $2,764,358 USD -18%
Accumulated Other Comprehensive Income (Loss), Net of Tax $10,634,714 USD -0.07%
Retained Earnings (Accumulated Deficit) $333,641,441 USD -3.9%
Stockholders' Equity Attributable to Parent $12,441,682 USD -36%
Liabilities and Equity $15,933,401 USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,631,163 USD 7.7%
Net Cash Provided by (Used in) Financing Activities $55,849 USD -100%
Net Cash Provided by (Used in) Investing Activities $7,978 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 8,192,538 shares 49%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14,640,533 USD -36%
Deferred Tax Assets, Valuation Allowance $56,349,279 USD 12%
Deferred Tax Assets, Gross $56,349,279 USD 12%
Payments to Acquire Property, Plant, and Equipment $7,978 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $12,606,904 USD 2.8%
Property, Plant and Equipment, Gross $153,962 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $48,568,167 USD 18%
Preferred Stock, Shares Authorized 40,000,000 shares 0%
Additional Paid in Capital $356,709,645 USD 1.6%
Depreciation, Depletion and Amortization $5,429 USD -12%
Share-based Payment Arrangement, Expense $100,000 USD -33%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%